Zacks: Brokerages Anticipate Can-Fite Biopharma Ltd (CANF) Will Announce Earnings of -$0.04 Per Share

Equities analysts predict that Can-Fite Biopharma Ltd (NASDAQ:CANF) will report earnings of ($0.04) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Can-Fite Biopharma’s earnings. Can-Fite Biopharma also reported earnings per share of ($0.04) during the same quarter last year. The firm is expected to announce its next earnings results on Monday, November 26th.

On average, analysts expect that Can-Fite Biopharma will report full-year earnings of ($0.16) per share for the current fiscal year. For the next year, analysts anticipate that the firm will report earnings of ($0.24) per share. Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that cover Can-Fite Biopharma.

Can-Fite Biopharma (NASDAQ:CANF) last issued its quarterly earnings data on Friday, August 31st. The company reported ($0.06) earnings per share for the quarter. The company had revenue of $0.27 million for the quarter, compared to the consensus estimate of $2.00 million.

Shares of Can-Fite Biopharma stock opened at $1.29 on Wednesday. Can-Fite Biopharma has a twelve month low of $1.12 and a twelve month high of $2.75.

Can-Fite Biopharma Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases, as well as sexual dysfunction. The company's lead drug candidate is CF101, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis.

See Also: Average Daily Trade Volume – ADTV

Get a free copy of the Zacks research report on Can-Fite Biopharma (CANF)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Can-Fite Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can-Fite Biopharma and related companies with's FREE daily email newsletter.

Leave a Reply